(Q53618660)

16 May 2018

title

Metallothioneins and resistance to cisplatin and radiation in prostate cancer. (English)

1 reference

16 May 2018

1 reference

David J Smith

1

1 reference

16 May 2018

Meena Jaggi

2

1 reference

16 May 2018

Wenguang Zhang

3

1 reference

16 May 2018

Anton Galich

4

1 reference

16 May 2018

Cheng Du

5

1 reference

16 May 2018

Samuel P Sterrett

6

1 reference

16 May 2018

Lynette M Smith

7

1 reference

16 May 2018

K C Balaji

8

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 June 2006

1 reference

16 May 2018

published in

Urology

1 reference

16 May 2018

volume

67

1 reference

16 May 2018

issue

6

1 reference

16 May 2018

page(s)

1341-1347

1 reference

16 May 2018

Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Metallothionein in carcinogenesis and cancer chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Metallothionein expression in human neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT-1X in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Brain, aging and neurodegeneration: role of zinc ion availability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Metallothionein in radiation exposure: its induction and protective role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Optimal administration schedule of cisplatin for bladder tumor with minimal induction of metallothionein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

Metallothionein 2A interacts with the kinase domain of PKCμ in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.12.032

10.1016/J.UROLOGY.2005.12.032

7 January 2021

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018